x
ServiziMenu principaleHome
You are here: Home > Events > Future Events > 4th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers
Print

4th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers

29.11.2019  -  01.12.2019

Milan, Italy

ADVANCED COURSES & SEMINARS

Rare brain cancers, Rare endocrine cancers, Rare gastro-intestinal cancers, Rare genito-urinary cancers, Rare gynaecological cancers, Rare head and neck cancers, Rare skin/eye melanoma, Rare thoracic cancers, Rare tumors, Sarcoma

*Third party registration should be used if you are requesting an individual registration for someone who is not you.
Please note that website registration under your name will be needed before registering someone else to this event.

Description

Chairs: J.Y. Blay, FR - P.G. Casali, IT - R.A. Stahel, CH


The “ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers” is an educational effort, on an annual basis, conceived to strengthen the education of medical professionals willing to devote their career to rare cancers.

Despite being rare as single entities, rare adult solid cancers account for as many as 15% of all new cancer cases, thus being the main group within rare cancers in general. The RARECARE project’s definition and list of 10 “families” of rare adult solid cancers, have been fundamental in shaping the sessions of this course:

• Rare skin cancers & non-cutaneous melanoma
• Rare thoracic tumors
• Rare female genital cancers
• Neuroendocrine tumors
• Endocrine gland tumors
• Sarcomas
• Digestive rare cancers
• Rare urological and male genital tumors
• Central nervous system neoplasms
• Head & neck cancers

Since ‘networking’ and ‘multidisciplinarity’ are the two keywords to improve quality of care of rare cancers, ESO has decided to develop the programme of this course in collaboration with all the European initiatives in this field and to give its contribution to tackle the rare cancer issue. The “4th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers” is conceived in the context of, and supported by the Joint Action on Rare Cancers of the European Union (JARC), a project coordinated by the Istituto Nazionale Tumori, Milan, and EURACAN, the European Reference Network on rare adult solid cancers. The Faculty has been largely selected from EURACAN, also with the aim of letting this educational effort closely interact with its networking activities and to help share the best knowledge and updates on these cancers.

The optimal management of rare adult solid cancers poses specific diagnostic and therapeutic challenges, which will be debated and addressed during the course through close interaction between opinion leaders and the participants. The sessions are designed to address the needs of oncologists wanting an update on the advancements in the clinical and research settings.
ESO is also pleased to help with the organization of the 3rd Rare Cancers Europe (RCE) training course for advocacy groups, which will be held in parallel sessions, with the aim to reinforce the relationship and exchange between physicians and patients representatives.

 

The course is an ESO-ESMO-RCE joint event                    
RCE         ESMO          
Held in collaboration with         In the framework of
 INT                



Invited faculty

INVITED FACULTY
M. Angi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
E. Baudin, Institut Gustave Roussy, Villejuif, FR
S. Bielack, Klinikum Stuttgart Olgahospital, Stuttgart, DE

J.Y. Blay, Centre Léon Bérard, Lyon, FR

P. Bruzzi, Istituto Nazionale Ricerca Cancro, Genoa, IT
P.G. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
S. Cavalieri, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. De Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A.P. Dei Tos, Azienda ULSS9, Treviso, IT
C. De La Fouchardière
, Centre Léon Bérard, Lyon, FR
F. De Lorenzo
, European Cancer Patient Coalition, Brussels, BE
M. Deraco, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Droz Dit Busset, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
H. Duffau, Hopital Gui de Chauliac, Montpellier, FR
J.G. Eriksen, Aarhus University Hospital, Aarhus, DK
N. Fazio, Istituto Europeo di Oncologia, Milan, IT
A.M. Frezza, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Garassino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
J.A. Gietema
, University Medical Center, Groningen, NL
R. Glynne-Jones, Mount Vernon Centre for Cancer Treatment, London, UK
S. Grisanti, A.O. Spedali Civili, Brescia, IT
A. Gronchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A. Idbaih, APHP Hopital de la Salpetriere, Paris, FR
E. Kapiteijn, Leiden University Medical Center, NL
C. Lebbé, Hopital St. Louis, Paris, FR
L. Licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
L. Locati, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
K. Newbold, The Royal Marsden NHS Foundation Trust, London, UK
N. Nicolai, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Niger, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
K. Oliver, International Brain Tumour Alliance, Tadworth, UK
F. Peccatori, European School of Oncology, Milan, IT
C. Piazza, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
S. Piperno-Neumann, Institut Curie, Paris, FR
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR
M. Seckl, Hammersmith Campus, London, UK
R. Soffietti, AOU San Giovanni Battista, Torino, IT
S. Stacchiotti, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
R.A. Stahel, Cancer Center University Hospital, Zurich, CH
A. Trama, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
L. Wyrwicz, Marie Curie Memorial Cancer Center, Warsaw, PL

General information

PARTICIPANT’S PROFILE
- Medical degree
- Specialization/residency in medical oncology, radiation oncology, surgical oncology or equivalent

LEARNING OBJECTIVES
Update on the latest clinical development with a background perspective on the state-of-the-art and evidence based practice.

CME PROVIDER
MZ CONGRESSI s.r.l.
ID no. 966
Via Carlo Farini, 81
Milan


ORGANISING SECRETARIAT

European School of Oncology
Rare Tumours Programme
c/o Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1
20133 Milano - Italy
Fax +39 0223902531
Email: raretumours@eso.net

VENUE
Fondazione Cariplo Conference Center
Via Romagnosi, 8
Milan
Italy

ACCREDITATION
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value.
The event is designated for a maximum of 16 European CME credits (ECMEC).
Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Furthermore, 12 Italian CME credits have been assigned.

BADGE
The badge is the only official evidence of registration and should be worn at all times during the event.

INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation during the Course. Participants are advised to take out their own personal and travel insurance.

OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.

IMPORTANT DEADLINES

Early registration: 31 October 2019  
Save event date: 29 November 2019  
Early registration by: insert the date  
Late registration by: insert the date  
Onsite registration from: insert the date  

 

 

 

Registration

REGISTRATION
Registration grants participation in all sessions, coffee breaks and lunches as indicated in the programme.
Interested oncologists should register online (at the top of this page).

Registration fees:

 

 Early
(by 31 October)

 Late
(From 1 November)

Registration fee
 EUR 250
 EUR 300
Club ESO and ESMO Members   EUR 200

Rates are quoted in Euro and include VAT.

CANCELLATION OF REGISTRATION OR REPLACEMENT
Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee less handling charges of EUR 80 will be refunded after the event, provided that the cancellation is received by ESO before 2  November. Replacements will be possible till 2 November.

PATIENT ADVOCATE REGISTRATION AND TRAVEL GRANT
Please contact RARE CANCERS EUROPE.
For information: rarecancerseurope@esmo.org


Programme

 29 November

10:30   Registration and coffee entry
11:00   Welcome from ESO and ESMO
F. Peccatori IT - R.A. Stahel, CH
INTRODUCTION (plenary session with PAGs)
11:20   The problem of rare cancers
P.G. Casali, IT
11:40   Networking on rare cancers
A.M. Frezza, IT
12:00   What can we do politically?
F. de Lorenzo, IT - K. Oliver, UK
KEYNOTE LECTURES
12:20   The epidemiological enigma of rare cancers
A. Trama, IT
12:40   Collaborative clinical registries in rare cancers: the ETOP-NTRK registry
R. Stahel, CH
13:00   Lunch
UPDATE ON CNS TUMORS
Moderators: R. Soffietti, IT - A. Idbaih, FR
14:00   Gliomas
R. Soffietti, IT
14:20   Rare CNS tumors
A. Idbaih, FR
14:40   Molecular approaches to CNS tumors
R. Soffietti, IT
15:00   New developments in surgery of CNS tumors
H. Duffau, FR
15:20   Discussion
15:50   Coffee break
UPDATE ON RARE THORACIC CANCERS
Moderators: M. Garassino, IT - R.A. Stahel, CH
16:20   Mesothelioma
R.A. Stahel, CH
16:40   Thymic tumors
M. Garassino, IT
17:00   Discussion
UPDATE ON RARE FEMALE GENITAL CANCERS
Moderators: M. Seckl, UK - F. Peccatori, IT
17:30   Non-epithelial ovarian tumors
I. Ray-Coquard, FR
17:50   Trophoblastic tumors
M. Seckl, UK
18:10   Discussion

 

 30 November


KEYNOTE LECTURE
8:30   The scope of pathologic diagnosis in rare cancers:
which molecular profiling should be provided today?
A.P. Dei Tos, IT
UPDATE ON RARE SKIN TUMORS & UVEAL MELANOMA Moderators: S. Piperno-Neumann, FR - E. Kapiteijn, NL
9:00   Merkel cell carcinoma
C. Lebbé, FR
9:20   Cutaneous adnexal malignancies
S. Cavalieri, IT
9:40   Uveal melanoma
M. Angi, IT
10:00   Discussion
10:30   Coffee break
Update on HEAD & NECK CANCERS
Moderators: J.G. Eriksen, DK - L. Licitra, IT
11:00   Laryngeal & hypopharyngeal carcinoma
L. Licitra, IT
11:20   Oropharyngeal carcinoma
J.G. Eriksen, DK
11:40   Nasopharyngeal carcinoma & sinonasal cancers
L. Licitra, IT
12:00   Salivary gland tumors
L. Locati, IT
12:20   Oral cavity tumors
C. Piazza, IT
12:40   Discussion
13:00   Lunch
UPDATE ON SARCOMAS
Moderators: P.G. Casali, IT - A. Gronchi, IT
14:00   Adult soft tissue sarcomas (STS)
P.G. Casali, IT
14:20   GIST
J.Y. Blay, FR
14:40   Preoperative chemo-radiation therapy in STS
A. Gronchi, IT
15:00   Rare bone sarcomas
S. Stacchiotti, IT
15:20   Ewing sarcoma and Osteosarcoma
S. Bielack, DE
15:40   Discussion
16:10   Coffee break
KEYNOTE LECTURE
16:40   Being histologically agnostic in rare cancers
J.Y. Blay, FR
UPDATE ON ENDOCRINE GLAND TUMORS
Moderators: C. De La Fouchardière, FR - L. Licitra, IT
17:00   Adrenal cancer
S. Grisanti, IT
17:20   Thyroid cancer
K. Newbold, UK
17:40   Discussion

 

1 December

KEYNOTE Lecture
8:30   Quality of evidence in rare cancers
P. Bruzzi
UPDATE ON DIGESTIVE RARE CANCERS
Moderators: L. Wyrwicz, PL - F. de Braud, IT
9:00   Biliary tumors
M. Niger, IT
9:20   Anal carcinoma
R. Glynne-Jones, UK
9:40   Peritoneal mesothelioma & pseudomyxoma peritonei
M. Deraco, IT
10:00   Discussion
10:30   Coffee break
UPDATE ON RARE UROGENITAL CANCERS
Moderators: J.A. Gietema, NL - N. Nicolai, IT
11:00   Testicular cancer
J.A. Gietema, NL 
11:20   Discussion
UPDATE ON NEUROENDOCRINE TUMORS
Moderators: M. Caplin, UK - F. De Braud, IT
11:40   Thoracic neuroendocrine tumors
E. Baudin, FR
12:00   Gastroenteropancreatic neuroendocrine tumors
N. Fazio, IT
12:20   Surgery in neuroendocrine tumors
M. Droz dit Busset, IT
12:40   Discussion
13:00   Closing

 

Follow us